02 Jul Prodesse announces licensure of two additional patents
Expands intellectual property portfolio for multiplexing, detection of prokaryotic organisms
MILWAUKEE – Prodesse Inc., a molecular diagnostics company focused on infectious disease, today announced that it has taken worldwide, non-exclusive sublicenses with Abbott for the Caskey (U.S. No. 5,582,989) and Stanbridge (U.S. No. 5,851,767) patents. These patents were exclusively licensed to Abbott, with the right to grant sublicenses, by the Baylor College of Medicine and the University of California, respectively. The Caskey patent covers molecular multiplexing and the Stanbridge patent covers molecular detection of prokaryotic organisms, virtually all of which are bacteria. The licenses further expand Prodesse’s intellectual property portfolio of real-time multiplexing patents, allowing the company to continue to develop and commercialize its expansive molecular diagnostics assay menu.
Prodesse is a biotechnology company focused on developing molecular diagnostic reagents for a variety of infectious disease applications. The company’s products are designed based on a combination of Prodesse’s patented technologies and other licensed technologies. Prodesse sells FDA 510(k) cleared products worldwide, CE Marked in vitro diagnostic kits outside the US and research use only kits worldwide. The company’s products can be used on multiple nucleic acid extraction and real-time PCR platforms. Prodesse also operates a CLIA certified laboratory for testing services in the Midwest area.